Soft tissue sarcomas (STSs) are a rare and highly heterogeneous group of tumours originating from mesenchymal cells, characterized by significant clinical and biological diversity. Due to this complexity, STSs present considerable challenges in both diagnosis and treatment, requiring an expert, multidisciplinary, and coordinated approach. To address these challenges, a multidisciplinary team of experts from the Spanish Group for Research in Sarcomas (GEIS) has developed a comprehensive, evidence-based consensus guideline that incorporates the latest advancements in biology, imaging techniques, and treatment options. The primary objective of this guideline is to provide clear and practical, up-to-date recommendations addressing the key questions that arise in the management of STSs. This approach aims to support therapeutic decision-making, enhance overall patient management, and ultimately improve clinical outcomes for patients affected by STSs. Key recommendations include the use of MRI as the preferred imaging modality prior to biopsy and ensuring that all patients are referred to specialised sarcoma centres with a multidisciplinary team for diagnosis and treatment.

Adolescent and young adult cancer survivors (AYACS) represent a specific cancer patient population with unique chronic health issues difficult to identify in early, reversible phases with standard monitoring protocols. This review, conducted by a group of Spanish experts, provides recommendations for managing AYACS, focusing on key areas, such as cardiac toxicities, neurotoxicity and neurocognitive disorders, metabolic syndrome, secondary primary malignancies, bone toxicities, sexuality and fertility, psychosocial aspects, and other treatment-related toxicities.